BioNTech SE (BNTX)
| Market Cap | 26.26B |
| Revenue (ttm) | 13.28B |
| Net Income (ttm) | 6.78B |
| Shares Out | 240.99M |
| EPS (ttm) | 26.89 |
| PE Ratio | 3.95 |
| Forward PE | 9.89 |
| Dividend | n/a |
| Ex-Dividend Date | Jun 2, 2022 |
| Volume | 642,723 |
| Open | 109.84 |
| Previous Close | 109.41 |
| Day's Range | 108.46 - 110.00 |
| 52-Week Range | 100.08 - 188.99 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 167.31 (+53.54%) |
| Earnings Date | May 8, 2023 |
About BNTX
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, ... [Read more]
Financial Performance
In 2022, BioNTech SE's revenue was 17.31 billion, a decrease of -8.78% compared to the previous year's 18.98 billion. Earnings were 9.43 billion, a decrease of -8.34%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for BNTX stock is "Buy." The 12-month stock price forecast is $167.31, which is an increase of 53.54% from the latest price.
News
BioNTech says drug from OncoC4 partnership shows promise in mid-stage trial
BioNTech said on Friday that a new cancer immunotherapy candidate that it is working on with U.S. partner OncoC4 Inc was shown to shrink tumours in close to 30% of participants in a mid-stage lung can...
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
MAINZ, Germany, and ROCKVILLE, Maryland, USA, June 2, 2023 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”), today announced positive preliminary data from the ong...
BioNTech is proceeding with COVID-shot in line with WHO guidance
Germany's BioNTech said it was on track to introduce a COVID-19 shot by the early fall in the northern hemisphere that is adapted to currently dominant virus variants in line with recommendations by t...
Report of new COVID wave in China pushes shares of vaccine makers higher
Dr. Kavita Patel, fmr. White House health policy director, joins 'Fast Money' to discuss the latest reports of a possible uptick of COVID cases in China, the immunity situation in the country, and the...
BioNTech Revenue Falls. Why the Stock Is Climbing Anyway.
BioNTech's first-quarter revenue falls from a year earlier as demand for Covid-19 vaccines wanes but still tops analysts' estimates.
BioNTech's stock jumps 4.3% premarket after earnings fall but top estimates
BioNTEch SE's stock BNTX rose 4.3% in premarket trade Monday, after the German biotech posted far stronger-than-expected first-quarter earnings, even as profit and revenue tumbled on lower demand for ...
BioNTech Announces First Quarter 2023 Financial Results and Corporate Update
COVID-19 vaccine franchise focused on vaccine adaptation readiness ahead of the fall season and advancing next generation vaccine candidates and combinations BioNTech and partner OncoC4 plan to start ...
FDA authorizes Pfizer-BioNTech booster for young kids with compromised immune systems
The U.S. Food and Drug Administration late Friday authorized Pfizer Inc. PFE and BioNTech SE BNTX COVID-19 bivalent vaccine for immunocompromised children. The shot, which would be a fourth dose in mo...
BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023
MAINZ, Germany , April 24, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2023 on Monday, May 8th, 2023. BioN...
BioNTech enters cancer drug partnership with DualityBio
BioNTech SE BNTX, +1.63% said Monday it has entered a partnership with Shanghai-based Duality Biologics to acclereate the development of antibody-drug conjugates to treat patients with cancer and auto...
BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
MAINZ, Germany and SHANGHAI, China, April 3, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co. Ltd. (“DualityBio”), a clinical-stage biotech company focusing on the disc...
BioNTech Announces New ADS Repurchase Program
MAINZ, Germany, March 28, 2023 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) today announced that it has entered into a new share repurchase program (the “Program”), purs...
BioNTech stock slumps on worse-than-expected drop in revenue
Don't Miss: Valley of Hype: The culture that built Elizabeth Holmes WATCH HERE: https://youtu.be/Sb179GLPNYE
BioNTech shares slip on gloomy Covid vaccine sales outlook
The shares initially fell by 6.4% to an intraday low of $119.98 a share before recovering most of those losses in late morning trading.
BioNTech Is Ripe For A Rebound In 2023
BioNTech (NASDAQ: BNTX) got a substantial boost from the pandemic and its mRNA vaccine, developed with Pfizer (NYSE: PFE). The stock has seen a substantial correction since then due to slowing COVID s...
BioNTech Stock Is Falling. Blame the Covid Vaccine Outlook.
The German biotech that partnered with Pfizer to develop a Covid-19 vaccine expects fewer vaccinations and lowered levels of boosting this year.
BioNTech stock falls as earnings beat expectations, but show falling demand for COVID-19 vaccines
The U.S.-listed shares of BioNTech SE BNTX, -0.92% fell 2.7% in premarket expectations, as profit and revenue beat expectations but fell from a year ago due to lower demand for COVID-19 vaccines, and ...
BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
Conference call and webcast scheduled for March 27 at 8:00 am ET (2:00 pm CET)
BioNTech inks deal with OncoC4 to develop cancer treatments
BioNTech SE BNTX, -1.76% will pay $200 million to the privately held OncoC4 Inc. as part of a deal to develop and commercialize OncoC4's monoclonal antibody treatment that is being tested in several c...
BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications
MAINZ, Germany and ROCKVILLE, Maryland, USA, March 20, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”), a clinical-stage biopharmaceutical company dedicated to the discovery ...
FDA updates authorization of BioNTech, Pfizer's bivalent booster for young children
The Food and Drug Administration on Tuesday said children between the ages of 6 months and 5 years old can now get a booster dose of BioNTech BNTX and Pfizer's PFE COVID-19 bivalent vaccine. The third...
BioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023
MAINZ, Germany , March 13, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2022 on Monday, Marc...
BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel
JERUSALEM, Israel, March 1, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech”, “the Company”) announced that the Company and the Weizmann Institute of Science (“Weizmann Institute”) signed a Memorandum of ...
BioNTech Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing Facility
MAINZ, Germany, February 2, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced construction completion of the Company's first proprietary plasmid DNA manufacturing facility...
Mergers and Acquisitions in 2023 Off To A Strong Start
Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $...